New drug shrinks kidney tumors before surgery in early trial
NCT ID NCT07226544
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug before their surgery to see if it shrinks the tumor. The main goal is to measure how many patients have their tumor shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
- Wheat germ supplement studied for immune boost in advanced cancer
- Gene test may guide kidney cancer therapy choice
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?